Karl serves as Vice President of Clinical Operations. He has more than 30 years of experience building clinical departments and managing clinical programs and was a key player in five product approvals. Previously, Karl was Executive Director of Clinical Operations at Triphase Accelerator, where he was responsible for conducting clinical studies in patients with multiple myeloma and glioblastoma, helping lead to Celgene’s acquisition of assets related to marizomib in 2016. Karl has experience in a broad base of therapeutic areas. He received his Pharm.D. at the University of the Pacific, completed a Clinical Residency in ICU Medicine at Veterans Association Medical Center in La Jolla, California, completed a Research Fellowship in Cardiology and Pharmacokinetics at University of Florida, and started his academic career at the University of Texas Health Science Center at San Antonio.